Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 151


A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.

Sanchorawala V, Palladini G, Kukreti V, Zonder JA, Cohen AD, Seldin DC, Dispenzieri A, Jaccard A, Schönland SO, Berg D, Yang H, Gupta N, Hui AM, Comenzo RL, Merlini G.

Blood. 2017 Aug 3;130(5):597-605. doi: 10.1182/blood-2017-03-771220. Epub 2017 May 26.


Modelling the implications of reducing smoking prevalence: the public health and economic benefits of achieving a 'tobacco-free' UK.

Hunt D, Knuchel-Takano A, Jaccard A, Bhimjiyani A, Retat L, Selvarajah C, Brown K, Webber LL, Brown M.

Tob Control. 2017 May 11. pii: tobaccocontrol-2016-053507. doi: 10.1136/tobaccocontrol-2016-053507. [Epub ahead of print]


Extended and standard duration weight-loss programme referrals for adults in primary care (WRAP): a randomised controlled trial.

Ahern AL, Wheeler GM, Aveyard P, Boyland EJ, Halford JCG, Mander AP, Woolston J, Thomson AM, Tsiountsioura M, Cole D, Mead BR, Irvine L, Turner D, Suhrcke M, Pimpin L, Retat L, Jaccard A, Webber L, Cohn SR, Jebb SA.

Lancet. 2017 Jun 3;389(10085):2214-2225. doi: 10.1016/S0140-6736(17)30647-5. Epub 2017 May 3.


[Classification and therapeutic management of monoclonal gammopathies of renal significance].

Javaugue V, Bouteau I, Sirac C, Quellard N, Diolez J, Colombo A, Desport E, Ecotière L, Goujon JM, Fermand JP, Touchard G, Jaccard A, Bridoux F.

Rev Med Interne. 2017 Apr 27. pii: S0248-8663(17)30105-4. doi: 10.1016/j.revmed.2017.03.012. [Epub ahead of print] French.


A major turning point in NK/T-cell lymphoma?

Jaccard A, Hermine O.

Blood. 2017 Apr 27;129(17):2342-2343. doi: 10.1182/blood-2017-03-769075. No abstract available.


Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.

Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, Arnulf B, Macro M, Belhadj K, Garderet L, Roussel M, Payen C, Mathiot C, Fermand JP, Meuleman N, Rollet S, Maglio ME, Zeytoonjian AA, Weller EA, Munshi N, Anderson KC, Richardson PG, Facon T, Avet-Loiseau H, Harousseau JL, Moreau P; IFM 2009 Study.

N Engl J Med. 2017 Apr 6;376(14):1311-1320. doi: 10.1056/NEJMoa1611750.


Performance and economic evaluation of the molecular detection of pathogens for patients with severe infections: the EVAMICA open-label, cluster-randomised, interventional crossover trial.

Cambau E, Durand-Zaleski I, Bretagne S, Brun-Buisson C, Cordonnier C, Duval X, Herwegh S, Pottecher J, Courcol R, Bastuji-Garin S; EVAMICA study team.

Intensive Care Med. 2017 Apr 3. doi: 10.1007/s00134-017-4766-4. [Epub ahead of print]


Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays.

Palladini G, Jaccard A, Milani P, Lavergne D, Foli A, Bender S, Lavatelli F, Bosoni T, Valentini V, Pirolini L, Ferraro G, Basset M, Russo F, Nuvolone M, Albertini R, Cogne M, Merlini G.

Clin Chem Lab Med. 2017 Mar 27. pii: /j/cclm.ahead-of-print/cclm-2016-1024/cclm-2016-1024.xml. doi: 10.1515/cclm-2016-1024. [Epub ahead of print]


Sequential cyclophosphamide-bortezomib-dexamethasone unmasks the harmful cardiac effect of dexamethasone in primary light-chain cardiac amyloidosis.

Le Bras F, Molinier-Frenkel V, Guellich A, Dupuis J, Belhadj K, Guendouz S, Ayad K, Colombat M, Benhaiem N, Tissot CM, Hulin A, Jaccard A, Damy T.

Eur J Cancer. 2017 May;76:183-187. doi: 10.1016/j.ejca.2017.02.004. Epub 2017 Mar 20.


Prevalence and prognostic impact of left-sided valve thickening in systemic light-chain amyloidosis.

Mohty D, Pradel S, Magne J, Fadel B, Boulogne C, Petitalot V, Raboukhi S, Darodes N, Damy T, Aboyans V, Jaccard A.

Clin Res Cardiol. 2017 May;106(5):331-340. doi: 10.1007/s00392-016-1058-x. Epub 2016 Dec 8.


Cost savings of home bortezomib injection in patients with multiple myeloma treated by a combination care in Outpatient Hospital and Hospital care at Home.

Touati M, Lamarsalle L, Moreau S, Vergnenègre F, Lefort S, Brillat C, Jeannet L, Lagarde A, Daulange A, Jaccard A, Vergnenègre A, Bordessoule D.

Support Care Cancer. 2016 Dec;24(12):5007-5014. Epub 2016 Aug 15.


Unravelling the immunopathological mechanisms of heavy chain deposition disease with implications for clinical management.

Bridoux F, Javaugue V, Bender S, Leroy F, Aucouturier P, Debiais-Delpech C, Goujon JM, Quellard N, Bonaud A, Clavel M, Trouillas P, Di Meo F, Gombert JM, Fermand JP, Jaccard A, Cogné M, Touchard G, Sirac C.

Kidney Int. 2017 Feb;91(2):423-434. doi: 10.1016/j.kint.2016.09.004. Epub 2016 Oct 20.


Identification of prognostic markers in transthyretin and AL cardiac amyloidosis.

Damy T, Jaccard A, Guellich A, Lavergne D, Galat A, Deux JF, Hittinger L, Dupuis J, Frenkel V, Rigaud C, Plante-Bordeneuve V, Bodez D, Mohty D.

Amyloid. 2016 Sep;23(3):194-202. Epub 2016 Sep 20.


A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study).

Michel M, Terriou L, Roudot-Thoraval F, Hamidou M, Ebbo M, Le Guenno G, Galicier L, Audia S, Royer B, Morin AS, Marie Michot J, Jaccard A, Frenzel L, Khellaf M, Godeau B.

Am J Hematol. 2017 Jan;92(1):23-27. doi: 10.1002/ajh.24570. Epub 2016 Nov 10.


Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection.

Arcaini L, Besson C, Frigeni M, Fontaine H, Goldaniga M, Casato M, Visentini M, Torres HA, Loustaud-Ratti V, Peveling-Oberhag J, Fabris P, Rossotti R, Zaja F, Rigacci L, Rattotti S, Bruno R, Merli M, Dorival C, Alric L, Jaccard A, Pol S, Carrat F, Ferretti VV, Visco C, Hermine O.

Blood. 2016 Nov 24;128(21):2527-2532. Epub 2016 Sep 7.


Exclusion of Patients with a Severe T-Cell Defect Improves the Definition of Common Variable Immunodeficiency.

Bertinchamp R, Gérard L, Boutboul D, Malphettes M, Fieschi C, Oksenhendler E; DEFI study group.

J Allergy Clin Immunol Pract. 2016 Nov - Dec;4(6):1147-1157. doi: 10.1016/j.jaip.2016.07.002. Epub 2016 Aug 10.


Thalidomide and POEMS syndrome: a cautious step forward.

Jaccard A, Magy L.

Lancet Neurol. 2016 Oct;15(11):1104-5. doi: 10.1016/S1474-4422(16)30176-4. Epub 2016 Aug 3. No abstract available.


Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study.

Reboursiere E, Le Bras F, Herbaux C, Gyan E, Clavert A, Morschhauser F, Malak S, Sibon D, Broussais F, Braun T, Fornecker LM, Garidi R, Tricot S, Houot R, Joly B, Abarah W, Choufi B, Pham AD, Gac AC, Fruchart C, Marin E, Safar V, Parcelier A, Maisonneuve H, Bachy E, Cartron G, Jaccard A, Tournilhac O, Rossi C, Schirmer L, Martignoles JA, Gaulard P, Tilly H, Damaj G; From the Lymphoma Study Association (LYSA) centers.

Oncotarget. 2016 Dec 20;7(51):85573-85583. doi: 10.18632/oncotarget.10764.


Current anti-myeloma therapies in renal manifestations of monoclonal light chain-associated Fanconi syndrome: a retrospective series of 49 patients.

Vignon M, Javaugue V, Alexander MP, El-Karoui K, Karras A, Roos-Weil D, Royer B, Asli B, Knebelmann B, Touchard G, Jaccard A, Arnulf B, Bridoux F, Leung N, Fermand JP.

Leukemia. 2017 Jan;31(1):123-129. doi: 10.1038/leu.2016.195. Epub 2016 Jul 20.


Short- and long-term outcomes of AL amyloidosis patients admitted into intensive care units.

Guinault D, Canet E, Huart A, Jaccard A, Ribes D, Lavayssiere L, Venot M, Cointault O, Roussel M, Nogier MB, Pichereau C, Lemiale V, Arnulf B, Attal M, Chauveau D, Azoulay E, Faguer S.

Br J Haematol. 2016 Sep;174(6):868-75. doi: 10.1111/bjh.14135. Epub 2016 Jun 12.


Supplemental Content

Loading ...
Support Center